CGEN

Business Context and Reporting Period

Compugen Ltd. (Nasdaq: CGEN), a biotechnology company based in Tel-Aviv, Israel, filed this Form 6-K on March 4, 2003, to report financial results for the fourth quarter and full year ended December 31, 2002. The company focuses on merging computational technologies with biology, chemistry, and medicine to enhance drug discovery and development.

Key Financial Metrics

Liquidity: As of December 31, 2002, the company held $67.3 million in cash, cash equivalents, and marketable securities. This represents a decrease of $11.2 million from the prior year-end balance of $78.5 million (derived from $70.6 million Q3 2002 balance minus $3.3 million decrease, though the text explicitly states a decrease of $11.2 million from Dec 31, 2001). The filing notes a decrease of $3.3 million from the September 30, 2002 balance of $70.6 million.

Material Changes vs. Prior Period

• Revenue Decline: Full-year 2002 revenues decreased slightly to $11.1 million from $11.4 million in 2001. Q4 2002 revenues dropped to $2.7 million from $3.1 million in Q4 2001.
• Improved Profitability: Net loss narrowed significantly for both the quarter and the full year. The full-year loss decreased by $2.9 million (19% improvement), and the Q4 loss decreased by $0.9 million (22% improvement).
• Expense Reduction: Total operating expenses decreased by $4.2 million for the full year, driven largely by a reduction in the non-cash amortization of deferred compensation (from $2.6 million in 2001 to $0.9 million in 2002).
• Grant Income: Research and development grants increased to $1.8 million in 2002 from $0.99 million in 2001, partially offsetting the decline in product and service revenues.

Guidance, Outlook, and Risks

2003 Guidance:

• Cash Burn: Anticipated to be in the range of $14 million to $16 million for calendar year 2003.
• Cash Balance: Expected year-end 2003 balance is approximately $52 million, representing more than three years of runway at the anticipated burn rate.
• Revenue: Budgeted at approximately $9 million for 2003, down from the $11.1 million actual in 2002.
• R&D Expenses: Expected to remain the largest expenditure category, accounting for over 50% of total operating expenses.

Management Commentary: CEO Mor Amitai highlighted the expansion of core technologies and the creation of a subsidiary, Evogene, to pursue agricultural biotechnology. The company secured new agreements with Abbott (LEADS platform) and Diagnostic Products Corporation (royalty-bearing agreement for cancer diagnostics).

Risks and Contingencies:

• High-Risk Programs: The "Chemistry" (small molecule lead creation) program is described as "high-risk, high-reward" with scientific rationale not yet fully validated.
• Revenue Timing: The "Medicine" (predictive drug response) area is not expected to generate revenue in 2003.
• Forward-Looking Statements: Results may differ due to changes in collaborator relationships, competitive products, and technological development risks.

Investor Verification Checklist

• Verify the sustainability of the $14-16 million cash burn rate given the reduction in 2003 revenue guidance.
• Confirm the status and validation progress of the "Chemistry" small molecule lead creation program, which requires additional resources.
• Monitor the execution of the new royalty-bearing agreement with Diagnostic Products Corporation and the LEADS platform agreement with Abbott.
• Assess the impact of the spin-off of Evogene on Compugen's focus and resource allocation.
• Review the composition of the $67.3 million cash balance to ensure liquidity remains sufficient for the projected three-year runway.